Galmed Pharmaceuticals Ltd (GLMD)

Apr 13, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

Apr 13, 2025

Apr 10, 2025

Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks

Apr 10, 2025

Apr 10, 2025

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - Yahoo Finance

Apr 10, 2025

Apr 06, 2025

Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 06, 2025

Apr 05, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World

Apr 05, 2025

Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia

Apr 04, 2025

Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 02, 2025

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance

Apr 02, 2025

Mar 28, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World

Mar 28, 2025

Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India

Mar 27, 2025

Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks

Mar 20, 2025

Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire

Mar 20, 2025

Mar 20, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 20, 2025

Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Mar 12, 2025

Feb 28, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia

Feb 27, 2025

Feb 26, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 24, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

Feb 24, 2025

Jan 31, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Jan 31, 2025

Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa

Dec 05, 2024

Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024

Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria

Nov 26, 2024

Nov 16, 2024

Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024

Nov 14, 2024

Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks

Nov 14, 2024

Nov 14, 2024

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 12, 2024

Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia

Nov 12, 2024

Nov 11, 2024

500: Something went wrong - Investing.com Canada

Nov 11, 2024

Oct 21, 2024

Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks

Oct 21, 2024